TISIDB

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF13892 DNA-binding domain PF09110 HAND PF00271 Helicase conserved C-terminal domain PF09111 SLIDE PF00176 SNF2 family N-terminal domain
Function	Helicase that possesses intrinsic ATP-dependent nucleosome-remodeling activity. Complexes containing SMARCA5 are capable of forming ordered nucleosome arrays on chromatin; this may require intact histone H4 tails. Also required for replication of pericentric heterochromatin in S-phase specifically in conjunction with BAZ1A. Probably plays a role in repression of polI dependent transcription of the rDNA locus, through the recruitment of the SIN3/HDAC1 corepressor complex to the rDNA promoter. Essential component of the WICH complex, a chromatin remodeling complex that mobilizes nucleosomes and reconfigures irregular chromatin to a regular nucleosomal array structure. The WICH complex regulates the transcription of various genes, has a role in RNA polymerase I and RNA polymerase III transcription, mediates the histone H2AX phosphorylation at 'Tyr-142', and is involved in the maintenance of chromatin structures during DNA replication processes. Essential component of the NoRC (nucleolar remodeling complex) complex, a complex that mediates silencing of a fraction of rDNA by recruiting histone-modifying enzymes and DNA methyltransferases, leading to heterochromatin formation and transcriptional silencing.

> Gene Ontology [ TOP ]
Biological Process	GO:0000183 chromatin silencing at rDNA GO:0006302 double-strand break repair GO:0006323 DNA packaging GO:0006333 chromatin assembly or disassembly GO:0006334 nucleosome assembly GO:0006336 DNA replication-independent nucleosome assembly GO:0006338 chromatin remodeling GO:0006342 chromatin silencing GO:0006352 DNA-templated transcription, initiation GO:0016458 gene silencing GO:0016584 nucleosome positioning GO:0031055 chromatin remodeling at centromere GO:0031497 chromatin assembly GO:0034080 CENP-A containing nucleosome assembly GO:0034508 centromere complex assembly GO:0034724 DNA replication-independent nucleosome organization GO:0034728 nucleosome organization GO:0040029 regulation of gene expression, epigenetic GO:0043044 ATP-dependent chromatin remodeling GO:0043486 histone exchange GO:0045814 negative regulation of gene expression, epigenetic GO:0045815 positive regulation of gene expression, epigenetic GO:0061641 CENP-A containing chromatin organization GO:0065004 protein-DNA complex assembly GO:0071103 DNA conformation change GO:0071824 protein-DNA complex subunit organization
Molecular Function	GO:0003682 chromatin binding GO:0004386 helicase activity GO:0016887 ATPase activity GO:0031491 nucleosome binding GO:0042393 histone binding
Cellular Component	GO:0000793 condensed chromosome GO:0005657 replication fork GO:0005677 chromatin silencing complex GO:0016589 NURF complex GO:0017053 transcriptional repressor complex GO:0031010 ISWI-type complex GO:0031213 RSF complex GO:0043596 nuclear replication fork GO:0044454 nuclear chromosome part GO:0070603 SWI/SNF superfamily-type complex GO:0090568 nuclear transcriptional repressor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5250924: B-WICH complex positively regulates rRNA expression R-HSA-1640170: Cell Cycle R-HSA-73886: Chromosome Maintenance R-HSA-5693606: DNA Double Strand Break Response R-HSA-5693532: DNA Double-Strand Break Repair R-HSA-73894: DNA Repair R-HSA-606279: Deposition of new CENPA-containing nucleosomes at the centromere R-HSA-212165: Epigenetic regulation of gene expression R-HSA-74160: Gene Expression R-HSA-5250941: Negative epigenetic regulation of rRNA expression R-HSA-427413: NoRC negatively regulates rRNA expression R-HSA-774815: Nucleosome assembly R-HSA-5250913: Positive epigenetic regulation of rRNA expression R-HSA-5693565: Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-5250924: B-WICH complex positively regulates rRNA expression
R-HSA-1640170: Cell Cycle
R-HSA-73886: Chromosome Maintenance
R-HSA-5693606: DNA Double Strand Break Response
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-606279: Deposition of new CENPA-containing nucleosomes at the centromere
R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-74160: Gene Expression
R-HSA-5250941: Negative epigenetic regulation of rRNA expression
R-HSA-427413: NoRC negatively regulates rRNA expression
R-HSA-774815: Nucleosome assembly
R-HSA-5250913: Positive epigenetic regulation of rRNA expression
R-HSA-5693565: Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SMARCA5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SMARCA5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.52	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SMARCA5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.16	0.549
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.205	0.909
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.126	0.925
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.025	0.924
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.068	0.977
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.144	0.962
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.087	0.846
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.18	0.929
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.028	0.99
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.519	0.636
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.98	0.56
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.047	0.381

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SMARCA5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	1.4	-1.4	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	1.7	-1.7	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SMARCA5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SMARCA5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SMARCA5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SMARCA5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SMARCA5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SMARCA5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SMARCA5
Name	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 5
Aliases	hSNF2H; hISWI; SNF2H; WCRF135; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin A5; ......
Chromosomal Location	4q31.1-q31.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SMARCA5 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SMARCA5.

ID	Name	Drug Type	Targets	#Targets
DB02379	Beta-D-Glucose	Small Molecule	AMY1A, AMY2A, AMY2B, GCK, GLT6D1, GNPDA1, HK1, IFNB1, KRTAP5-2, KR ......	22
DB02670	4-Deoxy-Alpha-D-Glucose	Small Molecule	SMARCA5	1

Browse SMARCA5